Vireo Growth Inc. (VREOF) SEC filings

VREOFOTCPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 11/30

$9.01+0.01 (+0.11%)

Close on Oct 19, 2026Market cap $443.48MP/E –Yield –

SEC filings

40 of Vireo Growth's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 12, 2026	SEC EDGAR
Current report	8-K	Nov 10, 2026	Nov 10, 2026	SEC EDGAR
Current report	8-K	Oct 2, 2026	Oct 8, 2026	SEC EDGAR
Current report	8-K	Aug 21, 2026	Aug 26, 2026	SEC EDGAR
Current report	8-K	Aug 13, 2026	Aug 18, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 14, 2026	SEC EDGAR
Current report	8-K	Aug 7, 2026	Aug 13, 2026	SEC EDGAR
Current report	8-K	Aug 11, 2026	Aug 11, 2026	SEC EDGAR
Current report	8-K	Jul 30, 2026	Aug 5, 2026	SEC EDGAR
Current report	8-K	Jul 26, 2026	Jul 30, 2026	SEC EDGAR
Current report	8-K	Jul 26, 2026	Jul 27, 2026	SEC EDGAR
Current report	8-K	Jul 19, 2026	Jul 23, 2026	SEC EDGAR
Current report	8-K	Jun 14, 2026	Jun 18, 2026	SEC EDGAR
Current report	8-K	Jun 5, 2026	Jun 11, 2026	SEC EDGAR
Current report	8-K	Jun 5, 2026	Jun 11, 2026	SEC EDGAR
Current report	8-K	Jun 5, 2026	Jun 9, 2026	SEC EDGAR
Current report	8-K	May 29, 2026	Jun 3, 2026	SEC EDGAR
Current report	8-K	May 26, 2026	May 29, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 12, 2026	SEC EDGAR
Current report	8-K	May 12, 2026	May 12, 2026	SEC EDGAR
Current report	8-K	Apr 29, 2026	May 5, 2026	SEC EDGAR
Proxy statement	DEF 14A	May 29, 2026	Apr 16, 2026	SEC EDGAR
Current report	8-K	Apr 8, 2026	Apr 14, 2026	SEC EDGAR
Current report	8-K	Mar 31, 2026	Apr 6, 2026	SEC EDGAR
Current report	8-K	Mar 24, 2026	Mar 30, 2026	SEC EDGAR
Current report	8-K	Mar 19, 2026	Mar 25, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 17, 2026	SEC EDGAR
Current report	8-K	Mar 17, 2026	Mar 17, 2026	SEC EDGAR
Current report	8-K	Dec 22, 2025	Dec 30, 2025	SEC EDGAR
Current report	8-K	Dec 19, 2025	Dec 29, 2025	SEC EDGAR
Current report	8-K	Dec 16, 2025	Dec 22, 2025	SEC EDGAR
Current report	8-K	Nov 13, 2025	Dec 10, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 12, 2025	SEC EDGAR
Current report	8-K	Nov 12, 2025	Nov 12, 2025	SEC EDGAR
Current report	8-K	Oct 29, 2025	Nov 3, 2025	SEC EDGAR
Current report	8-K	Oct 10, 2025	Oct 14, 2025	SEC EDGAR
Current report	8-K	Oct 2, 2025	Oct 8, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 13, 2025	SEC EDGAR
Current report	8-K	Aug 13, 2025	Aug 13, 2025	SEC EDGAR
Current report	8-K	Jul 7, 2025	Jul 11, 2025	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Vireo Growth's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-30 reverse split on Jun 5, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is VREOF.

Compare: VREOF vs AAWH · VREOF vs OGI · VREOF vs CRLBF · VREOF vs JUSH · VREOF vs TRLV

Revenue growth255.8% · median -4.3%

Gross margin47.4% · median 44.2%

Operating margin1.3% · median -1.0%

Company	Revenue	Growth
TRLV	$1.08B	-9.1%
VREOF	$673.67M	+255.8%
AAWH	$493.62M	-4.3%
JUSH	$276.54M	+6.2%
OGI	–	–
CRLBF	–	–

Company

Next earnings (est.): Mar 16, 2027, before open
Exchange: OTC
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 612
Held by institutions: 0.0%
Auditor: DAVIDSON & COMPANY LLP
SEC CIK: 1771706

Advertisement
300 × 250

See a number that looks wrong?